OA-03 Talquetamab (tal) + Teclistamab (tec) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 with >1 Year of Follow-Up
Clinical Lymphoma Myeloma and Leukemia（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined